Celltrion Pharm, Inc. (KOSDAQ:068760)
South Korea
· Delayed Price · Currency is KRW 57,700
-200 (-0.35%)
Apr 29, 2026, 3:30 PM KST
Celltrion Pharm Revenue
Celltrion Pharm had revenue of 85.55B KRW in the quarter ending March 31, 2021, with 92.73% growth. This brings the company's revenue in the last twelve months to 274.73B, up 53.21% year-over-year. In the year 2020, Celltrion Pharm had annual revenue of 233.57B with 34.61% growth.
Revenue (ttm)
274.73B
Revenue Growth
+53.21%
P/S Ratio
9.32
Revenue / Employee
837.59M
Employees
328
Market Cap
2,560.02B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2020 | 233.57B | 60.06B | 34.61% |
| Dec 31, 2019 | 173.51B | 26.63B | 18.13% |
| Dec 31, 2018 | 146.88B | 11.02B | 8.11% |
| Dec 31, 2017 | 135.86B | 31.05B | 29.62% |
| Dec 31, 2016 | 104.81B | 30.08B | 40.25% |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
| Dec 31, 2013 | Pro | Pro | Pro |
| Dec 31, 2012 | Pro | Pro | Pro |
| Dec 31, 2011 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Hanall Biopharma | 155.18B |
| Daewoong Pharmaceutical | 1,570.89B |
| GC Biopharma | 1,991.28B |
| Chong Kun Dang Pharmaceutical | 1,692.40B |
| DongKook Pharmaceutical | 926.88B |
| Hanmi Pharm. | 1,547.53B |
| Yuhan | 2,186.64B |
| Daewoong | 2,068.37B |